Oncobesity News Posts
As insurers struggle with GLP-1 drug costs, some seek to wean patients off
By Jamie Ducharme, KFF Health News After losing 50 pounds on the injectable weight loss medication Zepbound, Kyra Wensley received a surprising letter from her
The GLP-1 Oral Frontier: Novo Nordisk And Eli Lilly’s 100-Year Duel Enters Its Next Chapter
Post Content
Efficacy of GLP‐1 receptor agonists in patients with obesity and heart failure with preserved ejection fraction: A systematic review and meta‐analysis of randomised controlled trials
Abstract Aims Obesity increases the risk of heart failure with preserved ejection fraction (HFpEF). Glucagon-like-peptide-1 receptor agonists (GLP-1 RAs) appear to improve cardiovascular outcomes in
Does Medicare Cover GLP-1 Weight Loss Drugs Like Ozempic and Zepbound?
GLP-1 drugs, such as Ozempic, are reshaping diabetes care and weight loss. Find out if Medicare covers them and if they’re right for you.
Another Win for GLP-1s; Microbiome-Cancer Link Revisited; HPV Cancer Early Detection
(MedPage Today) — More good news for GLP-1 agonists, as patients with operable lung cancer and a history of exposure to the drugs had better
GLP-1 Drugs Associated With Lower Overall Cancer Risk
Obesity is a risk factor for several forms of cancer that comprise 40% of annual cancer diagnoses in the US. New findings published in JAMA
Ten ways diabetes and dementia are linked
Alones/Shutterstock.com The link between diabetes and dementia is becoming increasingly clear. New research shows how blood sugar problems affect brain health and vice versa. Here
GLP1 receptor agonists attenuate systemic inflammation through microbiota mediated enrichment of Faecalibacterium prausnitzii and Roseburia spp
This study investigated the comparative anti-inflammatory effects of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and nonsteroidal anti-inflammatory drugs (NSAIDs), with a particular focus on microbiota-mediated
Weight-loss drug boom has reached apparel store rack as America resizes
As more Americans use GLP-1 weight-loss drugs such as Ozempic, Zepbound, Wegovy and Mounjaro, the clothing industry rack is being resized, in surprising ways.
Are GLP-1 drugs safe for women planning pregnancy?
A study reveals rising GLP-1 prescriptions in young women, highlighting low contraception use and potential risks for unintended pregnancies and fetal outcomes.
GLP-1 Drugs Reduce Rheumatoid Arthritis Symptoms, Study Suggests
(MedPage Today) — Patients with rheumatoid arthritis (RA) who used GLP-1 receptor agonists had less disease activity and improved cardiovascular biomarkers, a small retrospective study
Recent Human Trials On Oral GLP-1 Medicines Are Showing A Lot Of Promise
Shutterstock GLP-1 drugs like semaglutide hit the world a few years ago and quickly became one of the most popular drugs on the market. Sold
More Data on GLP-1 Receptor Agonist Use and Cancer Risk
Data point to higher risk for some cancers and lower risk for others with GLP-1 use.
Patients Are Flocking to Plastic Surgeons for ‘Ozempic Butt’ Surgery
Photo Illustration by Thomas Levinson/The Daily Beast/Getty Ozempic butt. Mounjuro mound-loss. Whatever you want to call it, saggy bottoms are on the rise. These so-called
GLP-1 drug approvals: A breakdown
As of Sept. 10, the FDA has approved more than a dozen glucagon-like peptide-1 receptor agonists for diabetes, weight loss, cardiovascular disease and other indications.
TikTok is flooded with ‘GLP-1 patches,’ despite its ban on selling weight-loss products
GLP-1 patches are being pushed on TikTok Shop, despite the platform’s ban on selling weight-loss products. Recent posts flagged by Olivia Little of Media Matters
Unraveling the Safety Profile of GLP-1 Receptor Agonists: Mechanistic Insights with a Focus on Semaglutide
Publication date: Available online 10 September 2025 Source: European Journal of Medicinal Chemistry Author(s): Xinyi He, Zimo Zhao, Yan Sun, Xi Jiang
Palatinose enhances response of gut hormones GLP-1 and PYY
A study published in *Nutrients* highlights that Palatinose, a low-glycemic carbohydrate, enhances the release of gut hormones GLP-1 and PYY, which are beneficial for metabolic
Real-World Data Show Tirzepatide Benefit in Type 1 Diabetes
At least two retrospective observational studies now suggest that tirzepatide safely reduces weight, A1c, and insulin requirements in type 1 diabetes, with randomized control trial data to come. Medscape Medical News
Ozempic for cancer? Signs point to potential benefits of GLP-1s in oncology.
Growing research suggests various ways weight loss drugs could have an impact in cancer care.
GLP-1 Receptor Agonist Use Reduces Heart Failure Mortality
Losing weight improves health outcomes. To put it another way, carrying excess visceral fat tissue causes ongoing harm via a range of mechanisms connected to
Semaglutide attenuates diabetic retinopathy progression via ameliorating retinal vasculopathy and oxidative stress in vivo and in vitro
Abstract Background Diabetic retinopathy (DR) is a major complication of diabetes mellitus, characterised by retinal vasculopathy and oxidative stress. Semaglutide, a glucagon-like peptide-1 receptor agonist
Alcohol Use Disorder in the ED: Screening and MAUD
Authors: Nicholas S. Imperato, DO, MPH (@nickimperato14, Emergency Medicine Resident, Rutgers New Jersey Medical School); Howard A. Greller MD (@heshiegreshie.bsky.social, Medical Toxicology Fellowship Director, Emergency
No pain, no gain: Ozempic’s quest for market share
The shock success of GLP-1 treatments for obesity carries massive implications (https://www.breakingviews.com/columns/considered-view/obesity-drugs-everyone-is-double-edged-sword-2025-05-29/) for wealthy societies and manufacturers Novo Nordisk (https://www.breakingviews.com/columns/breaking-view/novo-nordisks-skinny-pipeline-demands-bulky-cure-2025-08-06/) and Eli Lilly alike. In
GLP-1s broke the system
The explosive rise of GLP-1 medications—such as Mounjaro, Ozempic, and Wegovy—has ignited more than just headlines. It has fundamentally shifted how Americans access and pay
Media visibility and costs of new medicines under examination—what does the media highlight?
A study conducted by the University of Eastern Finland and Fimea found that the Finnish news media has given GLP-1 agonists used to treat obesity,
Are GLP-1 receptor agonists a ‘magic bullet’ for cancer?
Nature Reviews Cancer, Published online: 10 September 2025; doi:10.1038/s41568-025-00874-z Glucagon-like peptide-1 (GLP-1) receptor agonists are widely prescribed for weight loss. Here, Hebert and colleagues discuss
WHO adds GLP-1 drugs for diabetes, others to essential medicines list
The committee said this decision provided clear guidance on which patients would most benefit from the therapies
Why microdosing Ozempic could become as common as taking a multivitamin
They may have gained popularity for diabetes and weight loss, but GLP-1 medications like Ozempic and Wegovy have been linked to ever-expanding health benefits. In
Scientists from Tufts create weight-loss drug dubbed ‘next Ozempic’ that’s twice as effective and has fewer side effects (affects not only GLP-1 and GIP, but also glucagon and peptide YY)
submitted by /u/upyoars [link] [comments]
Ozempic’s hidden pregnancy risk few women know about
Thousands of women are using GLP-1 drugs like Ozempic for weight loss without contraception, leading to unintended pregnancies and potential risks for unborn babies. Experts
HHS commission releases strategy for children’s health: 5 takeaways
The Make America Healthy Again Commission, a newly created advisory body under HHS, published a report on chronic disease and children’s health Sept. 9. The
Development of a potent Xenopus GLP-1-derived GLP-1/GIP/Y2 receptor tri-agonist for obesity and type 2 diabetes
Publication date: Available online 9 September 2025 Source: International Journal of Biological Macromolecules Author(s): Xiyu Liu, Binbin Gong, Ting Wang, Guoqiang Hu, Jing Han, Lidan
Nearly Half of Those With Diabetes Don’t Know They Have the Disease
A new study suggests that a large percentage of people with diabetes are unaware they have the disease. Justin Paget/Getty Images Researchers estimate that around
GLP-1 receptor agonists may improve lung cancer outcomes
Lung cancer patients who take medications called GLP-1 receptor agonists—commonly prescribed for weight loss and diabetes management—fare better than those who don’t, according to research
Will LLY’s Oncology Portfolio Provide Key Diversification Benefits?
Eli Lilly’s LLY extraordinary revenue expansion remains anchored in its cardiometabolic franchise, where blockbuster GLP-1 drugs Mounjaro and Zepbound powered $20.6 billion in sales during
Drug pricing watchdog finds weight-loss drugs are becoming more cost-effective
Popular GLP-1 weight-loss injections like Ozempic or WeGovy are now delivering greater value, according to a new report
Regeneron’s promising antibody for cat, birch allergies; Ascletis targets quarterly GLP-1 shot
Plus, news about Anavex, Alnylam, Rapport Therapeutics, Dianthus Therapeutics, Ultragenyx, Atom Therapeutics, Alchemab, BioMarin, Amgen, Kyowa Kirin and Bristol Myers Squibb: 🤧 Regeneron’s allergy drugs
STAT+: Lilly looks into gene therapies for obesity
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. It’s STAT’s
Pricing Group Says Weight-Loss Drugs Becoming More Cost-Effective
By Deena Beasley(Reuters) -An influential drug pricing watchdog on Tuesday said popular GLP-1 weight-loss injections have become more…